Schizophrenia Market

DelveInsight’s ‘Schizophrenia—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


The Schizophrenia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Schizophrenia market size from 2018 to 2030. The report also covers current Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Schizophrenia Disease Understanding and Treatment Algorithm

Overview

Schizophrenia is a severe mental disorder in which people interpret reality abnormally. It may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling. Contrary to public perception, Schizophrenia is not split personality or multiple personalities. Besides, it is not caused by childhood experiences, poor parenting, or lack of willpower, nor the symptoms are identical in each patient. In addition, the vast majority of people with Schizophrenia are not violent and do not pose a danger to others. The most common form is paranoid Schizophrenia or Schizophrenia with paranoia. People with paranoid Schizophrenia have an altered perception of reality. They may see or hear things that do not exist, speak in strange or confusing ways, believe that others are trying to harm them or feel like they are being watched continuously. This can cause relationship problems, disrupt normal daily activities like bathing, eating, or running errands, and lead to alcohol and drug abuse in an attempt to self-medicate.


Experts believe illness results from a combination of genetic and environmental causes. The chance of having Schizophrenia is 10% if an immediate family member (a parent or sibling) has the illness. The risk is as high as 65% for those who have an identical twin with Schizophrenia.


Schizophrenia Diagnosis

Diagnosing Schizophrenia is not easy. Sometimes using drugs, such as methamphetamines or LSD, can cause a person to have Schizophrenia-like symptoms. The difficulty of diagnosing this illness is compounded by the fact that many people who are diagnosed do not believe they have it. Lack of awareness is a common symptom of people diagnosed with Schizophrenia and greatly complicates treatment.


While there are no single physical or lab tests that can diagnose Schizophrenia, a health care provider who evaluates the symptoms and the course of a person’s illness over 6 months can help ensure a correct diagnosis. The health care provider must rule out other factors such as brain tumors, possible medical conditions, and other psychiatric diagnoses, such as bipolar disorder. To be diagnosed with Schizophrenia, a person must have two or more of the following symptoms occurring persistently in the context of reduced functioning:


  • Delusions
  • Hallucinations
  • Disorganized speech
  • Disorganized or catatonic behavior
  • Negative symptoms


Delusions or hallucinations alone can often be enough to lead to a diagnosis of Schizophrenia. Identifying it as early as possible improves greatly a person’s chances of managing the illness, reducing psychotic episodes, and recovering. People who receive good care during their first psychotic episode are admitted to the hospital less often and may require less time to control symptoms than those who don’t receive immediate help. The literature on the role of medicines early in treatment is evolving, but it is known that psychotherapy is essential.


The doctor or therapist bases his or her diagnosis on the person’s report of symptoms and his or her observation of the person’s attitude and behavior.


The doctor or therapist then determines if the person’s symptoms point to a specific disorder as outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which is published by the American Psychiatric Association and is the standard reference book for recognized mental illnesses. According to the DSM-5, a diagnosis of Schizophrenia is made if a person has two or more core symptoms, one of which must be hallucinations, delusions, or disorganized speech for at least one month. The other core symptoms are gross disorganization and diminished emotional expression. Other DSM-5 criteria for a diagnosis of Schizophrenia include:


  • The level of work, interpersonal relations, or self-care is significantly below what it was before the start of symptoms.
  • Signs of disturbance that have lasted at least 6 month
  • Schizoaffective disorder and depressive or bipolar disorders with psychotic symptoms have been ruled out.
  • The disturbance is not caused by substance abuse or another medical condition (Cleveland Clinic, 2018).


Schizophrenia, like most psychiatric diagnoses, remains a syndromic concept. The use of operational criteria, such as those embodied in DSM-510 or the WHO International Classification of Diseases (ICD), has provided a reliable approach to psychiatric diagnoses in the clinic. However, the assumption that the clinical syndromes defined in this way represent valid disease entities with distinct underlying causes and pathogenesis is increasingly being seen as having impeded research. Indeed, psychiatric diagnoses have the unusual feature of being simultaneously too broad and too narrow.


Schizophrenia Treatment

Schizophrenia is a lifelong condition, but effective treatment can help a person manage the symptoms, prevent relapses, and avoid hospitalization. It requires lifelong treatment, even when symptoms have subsided. The illness requires a combination of treatments, including medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently approved pharmacologic agents focus mainly on modulating dopamine, leaving patients with Schizophrenia to cope with considerable residual symptoms. Suboptimal treatment, significant AEs, and challenges related to nonadherence create a need for new agents to manage Schizophrenia better. The focus of treatment in Schizophrenia changes as individuals enter different phases of the illness. Antipsychotic medications are commonly used for the treatment and is grouped into two categories, one is “second-generation” (or “atypical”) that is applied to clozapine—all antipsychotics first marketed after clozapine was approved in 1989—, and other is “first-generation” which is applied to antipsychotics marketed previously. Recent clinical research, however, has strongly suggested that the distinction between first- and second-generation antipsychotics has questionable validity and is confusing. The pharmacologic properties, therapeutic effects, and adverse effects are not distinguished between and are heterogeneous within the groups. According to the American Psychiatric Association, second-generation (atypical) antipsychotics (SGAs)—except for clozapine—are the agents of choice for first-line treatment of Schizophrenia. Some antipsychotics may be given as an intramuscular or subcutaneous injection and are also known as long-acting injectable antipsychotics. They are usually given every 2–4 weeks, depending on the medication. Various therapies like Psychotherapy and psychosocial therapy are given to cope up with the symptoms.

Schizophrenia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Schizophrenia, Diagnosed Prevalent cases of Schizophrenia, Gender-specific Diagnosed Prevalent cases of Schizophrenia, Age-specific Diagnosed Prevalent cases of Schizophrenia, and Severity-specific Diagnosed Prevalent cases of Schizophrenia scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.


 Key Findings

This section provides glimpses of the Schizophrenia epidemiology in the 7MM.

  • Total prevalent population of Schizophrenia in the 7MM is estimated to be 5,969,144 in 2020. These cases of Schizophrenia in the 7MM is expected to increase throughout the study period, i.e., 2018–2030.
  • Total diagnosed prevalent population of Schizophrenia in the 7MM was observed to be 3,043,148 in 2020.
  • Among the European five countries, Germany has the highest diagnosed prevalent population followed by the United Kingdom and the France. On the other hand, Spain had the lowest diagnosed prevalent population.


According to DelveInsight, the majority of cases of Schizophrenia are male as compared to female, in the US and EU-5. But in Japan the diagnosed cases of females represents majority of the cases.

Country Wise-Schizophrenia Epidemiology

The epidemiology segment also provides the Schizophrenia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Schizophrenia Drug Chapters

This segment of the Schizophrenia report encloses the detailed analysis of the mid- and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.


Schizophrenia Emerging Drugs


Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories

Doria is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. It is a new long-acting injectable (LAI) intramuscular formulation of risperidone, for monthly administration without oral supplementation. As researchers suggest that the intramuscular route of administration is more effective compared to oral, hence Doria is expected to generate a highest market share compared to other therapies.


SEP-363856: Sunovion/PsychoGenics

SEP-363856 is an orally active, novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 1A (5-HT1A) agonist activity that is under investigation for the treatment of Schizophrenia and other psychiatric conditions. SEP-363856 was discovered utilizing a high throughput, high content, mouse-behavior phenotyping platform, in combination with in vitro screening, aimed at developing non-D2 (anti-target) compounds that could nevertheless retain efficacy across multiple animal models sensitive to D2-based pharmacological mechanisms. SEP-856 demonstrated broad efficacy in putative rodent models relating to aspects of Schizophrenia, including phencyclidine (PCP)-induced hyperactivity, prepulse inhibition, and PCP-induced deficits in social interaction. In addition to its favorable pharmacokinetic properties, lack of D2 receptor occupancy, and the absence of catalepsy, SEP-856’s broad profile was further highlighted by its robust suppression of rapid eye movement sleep in rats. Preclinical models suggest that SEP-363856 has the potential to treat the positive and negative symptoms of Schizophrenia. SEP-363856 is being studied in a global Phase III development program for Schizophrenia


Roluperidone (MIN-101): Minerva Neurosciences

Roluperidone is meant to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of Schizophrenia, such as hallucinations, delusions, agitation, thought, and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Additionally, blocking 5-HT2A promotes slow-wave sleep, a sleep stage often disrupted in patients with Schizophrenia. The drug is also meant to block a specific subtype of sigma receptor called sigma2, which is involved in movement control, psychotic symptom control, learning, and memory. Blocking sigma2 also modulates other neurotransmitters in the brain, in particular dopamine, which is important as individuals with Schizophrenia often have elevated levels of dopamine in their brains. Blocking sigma2 also increases calcium levels in neurons in the brain, which can improve memory. In December 2017, the company announced the screening of the first patient in the pivotal Phase III clinical trial of Roluperidone (Study MIN-101C07) as monotherapy for negative symptoms in patients diagnosed with Schizophrenia. However, the trial did not meet the primary and key secondary endpoints


Dexmedetomidine (BXCL501): BioXcel Therapeutics

BXCL501 is a potential first-in-class, a proprietary sublingual thin film of dexmedetomidine, and a selective alpha-2a receptor agonist for the treatment of acute agitation. The drug directly targets a causal agitation mechanism and has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. The drug is the company's most advanced neuroscience clinical program, being developed initially for the treatment of acute agitation in patients with Schizophrenia and bipolar disorders. BXCL501 is designed to be easy to administer and has shown a rapid onset of action in clinical studies. It has the potential to generate a calming effect without producing excessive sedation

More products and detail in the report…

List to be continued in the report……

Schizophrenia Market Outlook

With no cure for Schizophrenia, the main goals of Schizophrenia treatment include symptom targeting and prevention of relapsed cases. Pharmacological therapy plays a vital role in the treatment of this disease, where many mono and combination pharmacological therapies are available for treating Schizophrenia symptoms. Antipsychotics are the first choice among psychotropic agents used to treat Schizophrenia. For some patient groups, treatment strategies include the combination of neuroleptics and antiepileptics. As the prevalence of depressive symptoms in patients with Schizophrenia is relatively high, antidepressants are also often prescribed. Moreover, some evidence supports the use of combination therapy with antipsychotics and benzodiazepines. Finally, the use of certain anticholinergic drugs in conjunction with antipsychotics has been identified as an essential milestone in the treatment of Schizophrenia.


The treatment options for Schizophrenia include medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. New research combined with an increased understanding of the etiology and pathophysiology of Schizophrenia is leading to the development of novel agents to improve Schizophrenia management and to address the above-mentioned gaps.


Antipsychotic (AP) medications are recommended as first-line treatment for Schizophrenia and are classified as first-generation antipsychotics (FGA; or typical APs) and second-generation antipsychotics (SGA; or atypical APs). For each generation, both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are available.


There are several FDA approved products for Schizophrenia treatment, including Rexulti (brexpiprazole, Otsuka America Pharmaceutical/ Lundbeck), Caplyta (lumateperone/ ITI-007, Intra-Cellular Therapies), Latuda (lurasidone hydrochloride, Sunovion Pharmaceuticals/Sumitomo Dainippon Pharma), Vraylar (cariprazine, Gedeon Richter/AbbVie), Saphris (asenapine, Merck/AbbVie/Schering-Plough Corporation/Allergan), Abilify MyCite (aripiprazole tablets with the sensor, Otsuka Pharmaceutical), Secuado (asenapine/HP-3070, Noven Pharmaceuticals/Hisamitsu Pharmaceutical), Invega Sustenna (paliperidone palmitate, Janssen Pharmaceuticals), Adasuve (loxapine, Alexza Pharmaceuticals/Teva Pharmaceuticals), Invega Trinza (Janssen Pharmaceuticals), and several others.


Key Findings

  • The market size of Schizophrenia in the 7MM was USD 8,119 million in 2020.
  • Among the EU-5 countries, Germany, has the highest market size followed by the UK, and France. The lowest market size was estimated in Spain in 2017.
  • The current management of Schizophrenia is categorized into first-generation antipsychotics and second-generation antipsychotics. These are further categorized based on the route of administration, as oral, injectables, and other (sublingual, and transdermal patches). Due to more efficacy and comparative high cost, injectables occupy majority of the market share.
  • The market share developed by first-generation antipsychotics and second-generation antipsychotics in the year 2020 was USD 309 million, and USD 7,664 million, respectively in the 7MM.
  • The market size of injectables and orals of second-generation antipsychotics class, was estimated to be USD 3,916 million, and USD 3,665 million, respectively in 2020, in the 7MM.


Approximately 30% of individuals with Schizophrenia are considered resistant to currently available drug therapies. Furthermore, 80% to 90% of individuals experience a relapse at some point in the course of their illness, often related to nonadherence to maintenance therapy. Several researchers have identified several gaps in pharmacologic therapy for Schizophrenia, which include a need for agents that improve cognition, are capable of treating negative symptoms, improve treatment-resistant Schizophrenia, have improved AE profiles, and improve adherence. Novel therapies that attempt to fill these treatment gaps have recently been approved or are currently in development.


Market Outlook for Seven Major Markets

This section provides the total Schizophrenia market size and market size by therapies in the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Schizophrenia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2018–2030. The analysis covers Schizophrenia market uptake by drugs; patient uptake by therapies; and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Schizophrenia Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapies.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Schizophrenia emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Schizophrenia market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Schizophrenia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight has been provided into the Schizophrenia epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Schizophrenia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Schizophrenia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Schizophrenia market.

Report Highlights

  • The Schizophrenia market is anticipated to increase for the study period 2018–2030.
  • Paliperidone Palmitate 6-Month (PP6M) is projected to lead the market with the largest market share in 2030.
  • In the coming years, Schizophrenia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Schizophrenia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Schizophrenia. Launch of emerging therapies will significantly impact the Schizophrenia market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Schizophrenia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Schizophrenia Pipeline Analysis
  • Schizophrenia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Schizophrenia Report Key Strengths

  • 10-Years Forecast
  • 7MM Coverage
  • Schizophrenia Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Schizophrenia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Schizophrenia market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Schizophrenia total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Schizophrenia market size during the forecast period (2021–2030)?
  • At what CAGR, the Schizophrenia market is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the Schizophrenia market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Schizophrenia market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Schizophrenia?
  • What is the historical Schizophrenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Schizophrenia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Schizophrenia?
  • Out of the countries mentioned above, which country would have the highest number of Schizophrenia cases during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Schizophrenia along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Schizophrenia in the US and Europe?
  • What are the Schizophrenia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Schizophrenia?
  • How many therapies are developed by each company for the treatment of Schizophrenia?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Schizophrenia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Schizophrenia therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Schizophrenia and their status?
  • What are the key designations that have been granted for the emerging therapies for Schizophrenia?
  • What are the 7MM historical and forecasted market of Schizophrenia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Schizophrenia.
  • To understand the future market competition in the Schizophrenia market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Schizophrenia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Schizophrenia market.
  • To understand the future market competition in the Schizophrenia market.

1. Key Insights

2. Report Introduction

3. Schizophrenia Market Overview at a Glance

3.1. Market Share (%) Distribution of Schizophrenia in 2018

3.2. Market Share (%) Distribution of Schizophrenia in 2030

4. Executive Summary of Schizophrenia

5. Disease Background and Overview

5.1. Introduction

5.2. Early warning signs and symptoms of Schizophrenia

5.3. Risk factors of Schizophrenia

5.4. Subtypes of Schizophrenia

5.5. Mechanism of Schizophrenia

5.6. Genetics of Schizophrenia

5.7. Diagnosis

5.8. Differential Diagnosis

5.9. Treatment and Management

5.9.1. Acute-phase symptoms

5.9.1.1. Pre-treatment assessment

5.9.2. Medication (Antipsychotic)

5.9.3. Psychotherapy

5.9.4. Psychosocial Therapy

5.9.5. Electroconvulsive Therapy (ECT)

5.9.6. IPAP Schizophrenia Algorithm

5.9.7. Treatment guidelines

5.9.7.1. The American Psychiatric Association (APA) practice guideline for the treatment of patients with Schizophrenia

5.9.7.2. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations

5.9.7.3. Updated Schizophrenia port treatment recommendations: psychosocial treatment recommendations

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. Total Prevalent Cases of Schizophrenia in the 7MM

6.4. Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM

6.5. United States Epidemiology

6.5.1. Assumptions and Rationale

6.5.2. Prevalent Cases of Schizophrenia in the United States

6.5.3. Diagnosed prevalent cases of Schizophrenia in the United States

6.5.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in the United States

6.5.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in the United States

6.5.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in the United States

6.6. EU5 Epidemiology

6.6.1. Germany Epidemiology

6.6.1.1. Assumptions and Rationale

6.6.1.2. Prevalent Cases of Schizophrenia in Germany

6.6.1.3. Diagnosed prevalent cases of Schizophrenia in Germany

6.6.1.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Germany

6.6.1.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany

6.6.1.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Germany

6.6.2. France Epidemiology

6.6.2.1. Assumptions and Rationale

6.6.2.2. Prevalent Cases of Schizophrenia in France

6.6.2.3. Diagnosed Prevalent cases of Schizophrenia in France

6.6.2.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in France

6.6.2.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in France

6.6.2.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in France

6.6.3. Italy Epidemiology

6.6.3.1. Assumptions and Rationale

6.6.3.2. Prevalent Cases of Schizophrenia in Italy

6.6.3.3. Diagnosed Prevalent cases of Schizophrenia in Italy

6.6.3.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Italy

6.6.3.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Italy

6.6.3.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Italy

6.6.4. Spain Epidemiology

6.6.4.1. Assumptions and Rationale

6.6.4.2. Prevalent Cases of Schizophrenia in Spain

6.6.4.3. Diagnosed prevalent cases of Schizophrenia in Spain

6.6.4.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Spain

6.6.4.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Spain

6.6.4.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Spain

6.6.5. United Kingdom Epidemiology

6.6.5.1. Assumptions and Rationale

6.6.5.2. Prevalent Cases of Schizophrenia in the UK

6.6.5.3. Diagnosed Prevalent cases of Schizophrenia in the UK

6.6.5.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in the UK

6.6.5.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in the UK

6.6.5.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in the UK

6.7. Japan Epidemiology

6.7.1. Assumptions and Rationale

6.7.2. Prevalent Cases of Schizophrenia in Japan

6.7.3. Diagnosed Prevalent cases of Schizophrenia in Japan

6.7.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Japan

6.7.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Japan

6.7.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Japan

7. Organizations contributing towards

8. Patient Journey

9. Case Reports

10. Marketed Products

10.1. Key Cross

10.2. Rexulti (brexpiprazole/OPC-34712): Otsuka America Pharmaceutical/Lundbeck

10.2.1. Drug Description

10.2.2. Mechanism of Action

10.2.3. Regulatory Milestones

10.2.4. Clinical Development

10.2.5. Clinical Trials Information

10.2.6. Safety and Efficacy

10.2.7. Product Profile

10.3. Caplyta (lumateperone/ITI-007): Intra-Cellular Therapies

10.3.1. Drug Description

10.3.2. Mechanism of Action

10.3.3. Regulatory Milestones

10.3.4. Clinical Development

10.3.5. Clinical Trials Information

10.3.6. Safety and Efficacy

10.3.7. Product Profile

10.4. Latuda (lurasidone hydrochloride): Sunovion Pharmaceuticals/Sumitomo Dainippon Pharma

10.4.1. Drug Description

10.4.2. Mechanism of Action

10.4.3. Regulatory Milestones

10.4.4. Clinical Development

10.4.5. Clinical Trials Information

10.4.6. Safety and Efficacy

10.4.7. Product Profile

10.5. Saphris (asenapine): Merck/AbbVie/Schering-Plough Corporation/Allerga

10.5.1. Drug Description

10.5.2. Mechanism of Action

10.5.3. Regulatory Milestones

10.5.4. Safety and Efficacy

10.5.5. Product Profile

10.6. Abilify MyCite (aripiprazole tablets with sensor): Otsuka Pharmaceutical

10.6.1. Drug Description

10.6.2. Mechanism of Action

10.6.3. Regulatory Milestones

10.6.4. Clinical Development

10.6.5. Clinical Trials Information

10.6.6. Safety and Efficacy

10.6.7. Product Profile

10.7. Invega Sustenna (paliperidone palmitate): Janssen Research & Development

10.7.1. Product Description

10.7.2. Regulatory Milestones

10.7.3. Clinical Development

10.7.4. Clinical Trials Information

10.7.5. Safety and Efficacy

10.7.6. Product Profile

10.8. Vraylar/Reagila (cariprazine): Gedeon Richter/AbbVie

10.8.1. Drug Description

10.8.2. Regulatory Milestones

10.8.3. Clinical Development

10.8.4. Clinical Trials Information

10.8.5. Safety and Efficacy

10.8.6. Product Profile

10.9. Adasuve (loxapine): Alexza Pharmaceuticals

10.9.1. Product Description

10.9.2. Regulatory Milestones

10.9.3. Clinical Development

10.9.4. Clinical Trials Information

10.9.5. Safety and Efficacy

10.9.6. Product Profile

10.10. Secuado (asenapine/HP-3070): Noven Pharmaceuticals/Hisamitsu Pharmaceutical

10.10.1. Drug Description

10.10.2. Regulatory Milestones

10.10.3. Clinical Development

10.10.4. Clinical Trials Information

10.10.5. Safety and Efficacy

10.10.6. Product Profile

10.11. Invega Trinza: Janssen Pharmaceuticals

10.11.1. Drug Description

10.11.2. Regulatory Milestones

10.11.3. Clinical Development

10.11.4. Clinical Trials Information

10.11.5. Safety and Efficacy

10.11.6. Product Profile

10.12. Aristada and Aristada Initio: Alkermes

10.12.1. Drug Description

10.12.2. Mechanism of Action

10.12.3. Regulatory Milestones

10.12.4. Clinical Development

10.12.5. Clinical Trials Information

10.12.6. Safety and Efficacy

10.12.7. Product Profile

10.13. Perseris (risperidone): Indivior

10.13.1. Drug Description

10.13.2. Mechanism of Action

10.13.3. Regulatory Milestones

10.13.4. Clinical Development

10.13.5. Clinical Trials Information

10.13.6. Safety and Efficacy

10.13.7. Product Profile

11. Emerging Therapies

11.1. Key Cross

11.2. Evenamide (NW-3509/NW-3509A): Newron Pharmaceuticals

11.2.1. Drug Description

11.2.2. Other Developmental Activity

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. CTP-692: Concert Pharmaceuticals

11.3.1. Product Description

11.3.2. Other Developmental Activity

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.4. PF-06412562: Cerevel Therapeutics/Pfizer

11.4.1. Product Description

11.4.2. Other developmental activity

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.5. Ralmitaront (RO6889450/RG-7906): Roche

11.5.1. Product Description

11.5.2. Clinical Development

11.5.3. Clinical Trials Information

11.5.4. Product Profile

11.6. BIIB104 (AMPA): Biogen

11.6.1. Product Description

11.6.2. Other developmental activity

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Safety and Efficacy

11.6.6. Product Profile

11.7. TAK-831: Takeda

11.7.1. Product Description

11.7.2. Other Developmental Activities

11.7.3. Clinical Development

11.7.4. Clinical Trials Information

11.7.5. Safety and Efficacy

11.7.6. Product Profile

11.8. NaBen (Sodium Benzoate): SyneuRx International

11.8.1. Product Description

11.8.2. Other Developmental Activities

11.8.3. Clinical Development

11.8.4. Clinical Trials Information

11.8.5. Product Profile

11.9. Paliperidone Palmitate 6-Month (PP6M): Janssen Pharmaceutical

11.9.1. Drug Description

11.9.2. Other Developmental Activities

11.9.3. Clinical Development

11.9.4. Clinical Trials Information

11.9.5. Safety and Efficacy

11.9.6. Product Profile

11.10. LYN-005: Lyndra Therapeutics

11.10.1. Drug Description

11.10.2. Clinical Development

11.10.3. Clinical Trials Information

11.10.4. Safety and Efficacy

11.10.5. Product Profile

11.11. Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories

11.11.1. Product Description

11.11.2. Other Developmental Activities

11.11.3. Clinical Development

11.11.4. Clinical Trials Information

11.11.5. Safety and Efficacy

11.11.6. Product Profile

11.12. Roluperidone (MIN-101): Minerva Neurosciences

11.12.1. Product Description

11.12.2. Other Developmental Activities

11.12.3. Clinical Development

11.12.4. Clinical Trials Information

11.12.5. Safety and Efficacy

11.12.6. Product Profile

11.13. SEP-363856: Sunovion/PsychoGenics

11.13.1. Product Description

11.13.2. Other Developmental Activities

11.13.3. Clinical Development

11.13.4. Clinical Trials Information

11.13.5. Safety and Efficacy

11.13.6. Product Profile

11.14. Nuplazd (Pimavanserin): Acadia Pharmaceuticals

11.14.1. Product Description

11.14.2. Other developmental activity

11.14.3. Clinical Development

11.14.4. Clinical Trials Information

11.14.5. Safety and Efficacy

11.14.6. Product Profile

11.15. Encenicline (EVP-6124): Forum Pharmaceuticals

11.15.1. Product Description

11.15.2. Other developmental activity

11.15.3. Clinical Development

11.15.4. Clinical Trials Information

11.15.5. Safety and Efficacy

11.15.6. Product Profile

11.16. Dexmedetomidine (BXCL501): BioXcel Therapeutics

11.16.1. Product Description

11.16.2. Other Developmental Activities

11.16.3. Clinical Development

11.16.4. Clinical Trials Information

11.16.5. Safety and Efficacy

11.16.6. Product Profile

11.17. Avisetron (AVN-211): Avineuro Pharmaceuticals

11.17.1. Product Description

11.17.2. Other Developmental Activity

11.17.3. Clinical Development

11.17.4. Safety and Efficacy

11.17.5. Product Profile

11.18. ALKS 3831 (Olanzapine + Samidorphan): Alkermes

11.18.1. Product Description

11.18.2. Other Developmental Activities

11.18.3. Clinical Development

11.18.4. Clinical Trials Information

11.18.5. Safety and Efficacy

11.18.6. Product Profile

11.19. AVP-786: Avanir Pharmaceuticals/Otsuka Pharmaceutical/Concert Pharmaceuticals

11.19.1. Product Description

11.19.2. Other Developmental Activities

11.19.3. Clinical Development

11.19.4. Clinical Trials Information

11.19.5. Product Profile

11.20. Lu AF11167: H. Lundbeck A/S

11.20.1. Product Description

11.20.2. Other Developmental Activities

11.20.3. Clinical Development

11.20.4. Clinical Trials Information

11.20.5. Product Profile

11.21. GWP42003 (Cannabidiol/GWP42003-P): GW Research

11.21.1. Product Description

11.21.2. Clinical Development

11.21.3. Clinical Trials Information

11.21.4. Safety and Efficacy

11.21.5. Product Profile

11.22. BI 409306: Boehringer Ingelheim

11.22.1. Product Description

11.22.2. Other Developmental Activities

11.22.3. Clinical Development

11.22.4. Clinical Trials Information

11.22.5. Safety and Efficacy

11.22.6. Product Profile

11.23. KarXT: Karuna Pharmaceuticals

11.23.1. Product Description

11.23.2. Other developmental activity

11.23.3. Clinical Development

11.23.4. Clinical Trials Information

11.23.5. Safety and Efficacy

11.23.6. Product Profile

11.24. CPL500036: Celon Pharma

11.24.1. Drug Description

11.24.2. Other Developmental Activities

11.24.3. Clinical Development

11.24.4. Clinical Trials Information

11.24.5. Safety and Efficacy

11.24.6. Product Profile

11.25. MK-8189: Merck

11.25.1. Drug Description

11.25.2. Clinical Development

11.25.3. Clinical Trials Information

11.25.4. Safety and Efficacy

11.25.5. Product Profile

11.26. Miricorilant: Corcept Therapeutics

11.26.1. Drug Description

11.26.2. Clinical Development

11.26.3. Clinical Trials Information

11.26.4. Safety and Efficacy

11.26.5. Product Profile

11.27. BI 425809: Boehringer Ingelheim

11.27.1. Drug Description

11.27.2. Other Developmental Activities

11.27.3. Clinical Development

11.27.4. Clinical Trials Information

11.27.5. Safety and Efficacy

11.27.6. Product Profile

12. Evolution of Long-Acting Injectable (LAI) Antipsychotics

13. Top-level Comparison of First-generation and Second-generation Antipsychotics

14. Schizophrenia: Seven Major Market Analysis

14.1. Key Findings

14.2. Market Methodology

14.3. Market Size of Schizophrenia in the 7MM

14.4. Market Size of Schizophrenia by Therapies in the 7MM

14.4.1. Market Size of Schizophrenia by Class in the 7MM

14.4.2. Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM

14.5. Market Outlook

14.6. Attribute Analysis

14.7. Key Market Forecast Assumptions

14.8. United States Market Outlook

14.8.1. United States Market Size

14.8.1.1. Total market size of Schizophrenia in the United States

14.8.1.2. Market Size of Schizophrenia by Therapies in the US

14.9. EU-5 Market Outlook

14.9.1. Germany Market Size

14.9.1.1. Total Market size of Schizophrenia in Germany

14.9.1.2. Market Size of Schizophrenia by Therapies in Germany

14.9.2. France Market Size

14.9.2.1. Total Market size of Schizophrenia in France

14.9.2.2. Market Size of Schizophrenia by Therapies in France

14.9.3. Italy Market Size

14.9.3.1. Total Market size of Schizophrenia in Italy

14.9.3.2. Market Size of Schizophrenia by Therapies in Italy

14.9.4. Spain Market Size

14.9.4.1. Total Market size of Schizophrenia in Spain

14.9.4.2. Market Size of Schizophrenia by Therapies in Spain

14.9.5. United Kingdom Market Size

14.9.5.1. Total Market size of Schizophrenia in the United Kingdom

14.9.5.2. Market Size of Schizophrenia by Therapies in the UK

14.10. Japan Market Outlook

14.10.1. Japan Market Size

14.10.1.1. Total Market size of Schizophrenia in Japan

14.10.1.2. Market Size of Schizophrenia by Therapies in Japan

15. KOL Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Unmet Needs

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Schizophrenia, Market, Epidemiology and Key Events (2017–2030)

Table 2: Early symptoms of Schizophrenia

Table 3: Symptoms of Schizophrenia

Table 4: Clinical features of Schizophrenia, bipolar disorder, schizoaffective disorder, autism, and ADHD

Table 5: Antipsychotic medications: available oral and short-acting intramuscular formulations and dosing considerations

Table 6: Long-acting injectable antipsychotic medications: dosing

Table 7: Total Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Table 8: Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Table 9: Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Table 10: Diagnosed Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Table 11: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Table 12: Age-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Table 13: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Table 14: Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 15: Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 16: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 17: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 18: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 19: Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 20: Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 21: Gender-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 22: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 23: Severity-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 24: Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 25: Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 26: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 27: Age-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 28: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 29: Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 30: Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 31: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 32: Age-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 33: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 34: Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 35: Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 36: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 37: Age-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 38: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 39: Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 40: Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 41: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 42: Age-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 43: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 44: Organizations contributing toward Schizophrenia

Table 45: Key Cross of Marketed Drugs

Table 46: Rexulti (brexpiprazole), Clinical Trial Description, 2021

Table 47: Caplyta (lumateperone/ ITI-007), Clinical Trial Description, 2021

Table 48: Latuda, Clinical Trial Description, 2021

Table 49: Abilify MyCite, Clinical Trial Description, 2021

Table 50: Invega Sustenna (paliperidone palmitate), Clinical Trial Description, 2021

Table 51: Vraylar, Clinical Trial Description, 2021

Table 52: Adasuve, Clinical Trial Description, 2021

Table 53: Secuado, Clinical Trial Description, 2021

Table 54: Invega Trinza, Clinical Trial Description, 2021

Table 55: Aristada, Clinical Trial Description, 2021

Table 56: Perseris, Clinical Trial Description, 2021

Table 57: Key Cross of Emerging Drug

Table 58: Evenamide, Clinical Trial Description, 2021

Table 59: CTP-692, Clinical Trial Description, 2021

Table 60: PF 06412562, Clinical Trial Description, 2021

Table 61: RO6889450, Clinical Trial Description, 2021

Table 62: BIIB104, Clinical Trial Description 2021

Table 63: TAK-831, Clinical Trial Description, 2021

Table 64: NaBen (Sodium Benzoate), Clinical Trial Description, 2021

Table 65: Paliperidone Palmitate 6-Month (PP6M), Clinical Trial Description, 2021

Table 66: LYN-005, Clinical Trial Description, 2021

Table 67: Doria (risperidone ISM), Clinical Trial Description, 2021

Table 68: Roluperidone, Clinical Trial Description, 2021

Table 69: SEP-363856, Clinical Trial Description, 2021

Table 70: Pimavanserin, Clinical Trial Description 2021

Table 71: EVP-6124, Clinical Trial Description, 2021

Table 72: BXCL501, Clinical Trial Description, 2021

Table 73: ALKS 3831, Clinical Trial Description, 2021

Table 74: AVP-786, Clinical Trial Description, 2021

Table 75: Lu AF11167, Clinical Trial Description, 2021

Table 76: GWP42003 (Cannabidiol/GWP42003-P), Clinical Trial Description, 2021

Table 77: BI 409306, Clinical Trial Description, 2021

Table 78: KarXT, Clinical Trial Description, 2021

Table 79: CPL500036 Clinical Trial Description, 2021

Table 80: MK-8189 Clinical Trial Description, 2021

Table 81: Miricorilant (CORT118335) Clinical Trial Description, 2021

Table 82: BI 425809, Clinical Trial Description, 2021

Table 83: Market Size of Schizophrenia in the 7MM, USD Million (2018–2030)

Table 84: Market Size of Schizophrenia by Class in the 7MM, USD Million (2018–2030)

Table 85: Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM, USD Million (2018–2030)

Table 86: Key Market Forecast Assumptions for Roluperidone (MIN-101)

Table 87: Key Market Forecast Assumptions for Dexmedetomidine (BXCL501)

Table 88: Key Market Forecast Assumptions for SEP363856

Table 89: Key Market Forecast Assumptions for Pimavanserin

Table 90: Key Market Forecast Assumptions for Risperidone ISM (DORIA)

Table 91: Key Market Forecast Assumptions for ALKS 3831

Table 92: Key Market Forecast Assumptions for Evenamide

Table 93: Key Market Forecast Assumptions for BI 409306

Table 94: Key Market Forecast Assumptions for GWP42003-P

Table 95: Key Market Forecast Assumptions for KarXT

Table 96: Key Market Forecast Assumptions for LYN-005

Table 97: Key Market Forecast Assumptions for Paliperidone Palmitate 6-Month (PP6M)

Table 98: The US Market Size of Schizophrenia in USD Million (2018–2030)

Table 99: Market Size of Schizophrenia by Class in the US, USD Million (2018–2030)

Table 100: Market Size of Schizophrenia by Current and Emerging Therapies in the US, USD Million (2018–2030)

Table 101: Germany Market Size of Schizophrenia in USD Million (2018–2030)

Table 102: Market Size of Schizophrenia by Class in Germany, USD Million (2018–2030)

Table 103: Market Size of Schizophrenia by Current and Emerging Therapies in Germany, USD Million (2018–2030)

Table 104: France Market Size of Schizophrenia in USD Million (2018–2030)

Table 105: Market Size of Schizophrenia by Class in France, USD Million (2018–2030)

Table 106: Market Size of Schizophrenia by Current and Emerging Therapies in France, USD Million (2018–2030)

Table 107: Italy Market Size of Schizophrenia in USD Million (2018–2030)

Table 108: Market Size of Schizophrenia by Class in Italy, USD Million (2018–2030)

Table 109: Market Size of Schizophrenia by Current and Emerging Therapies in Italy, USD Million (2018–2030)

Table 110: Spain Market Size of Schizophrenia in USD Million (2018–2030)

Table 111: Market Size of Schizophrenia by Class in Spain, USD Million (2018–2030)

Table 112: Market Size of Schizophrenia by Current and Emerging Therapies in Spain, USD Million (2018–2030)

Table 113: The UK Market Size of Schizophrenia in USD Million (2018–2030)

Table 114: Market Size of Schizophrenia by Class in the UK, USD Million (2018–2030)

Table 115: Market Size of Schizophrenia by Current and Emerging Therapies in the UK, USD Million (2018–2030)

Table 116: Japan Market Size of Schizophrenia in USD Million (2018–2030)

Table 117: Market Size of Schizophrenia by Class in Japan, USD Million (2018–2030)

Table 118: Market Size of Schizophrenia by Current and Emerging Therapies in Japan, USD Million (2018–2030)

List of Figures

Figure 1: Overview of Schizophrenia

Figure 2: Interaction of genetic and environmental risk factors in the developmental pathology of Schizophrenia

Figure 3: Neuron–glia interactions in the cerebral cortex—key neural substrates for the pathology of Schizophrenia

Figure 4: Schematic representation of drug actions that normalize aberrant glutamate neurotransmission in the prefrontal cortex of schizophrenics

Figure 5: A representative molecular pathway for Schizophrenia—fine-tuning of the glutamate synapse

Figure 6: Treatment approaches of Schizophrenia

Figure 7: Types of medications to treat Schizophrenia

Figure 8: Types of Psychotherapy to treat Schizophrenia

Figure 9: Schizophrenia Algorithm

Figure 10: Total Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Figure 11: Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Figure 12: Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Figure 13: Diagnosed Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Figure 14: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Figure 15: Age-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Figure 16: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Figure 17: Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 18: Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 19: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 20: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 21: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 22: Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 23: Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 24: Gender-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 25: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 26: Severity-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 27: Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 28: Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 29: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 30: Age-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 31: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 32: Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 33: Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 34: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 35: Age-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 36: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 37: Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 38: Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 39: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 40: Age-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 41: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 42: Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 43: Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 44: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 45: Age-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 46: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 47: Market Size of Schizophrenia in the 7MM, USD Millions (2018–2030)

Figure 48: Market Size of Schizophrenia by Class in the 7MM, USD Millions (2018–2030)

Figure 49: Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM, USD Millions (2018–2030)

Figure 50: Market Size of Schizophrenia in the US, USD Millions (2018–2030)

Figure 51: Market Size of Schizophrenia by Class in the US, in USD Million (2018–2030)

Figure 52: Market Size of Schizophrenia by Current and Emerging Therapies in the US, in USD Million (2018–2030)

Figure 53: Market Size of Schizophrenia in Germany, USD Millions (2018–2030)

Figure 54: Market Size of Schizophrenia by Class in Germany, in USD Million (2018–2030)

Figure 55: Market Size of Schizophrenia by Current and Emerging Therapies in Germany, in USD Million (2018–2030)

Figure 56: Market Size of Schizophrenia in France, USD Millions (2018–2030)

Figure 57: Market Size of Schizophrenia by Class in France, in USD Million (2018–2030)

Figure 58: Market Size of Schizophrenia by Current and Emerging Therapies in France, in USD Million (2018–2030)

Figure 59: Market Size of Schizophrenia in Italy, USD Millions (2018–2030)

Figure 60: Market Size of Schizophrenia by Class in Italy, in USD Million (2018–2030)

Figure 61: Market Size of Schizophrenia by Current and Emerging Therapies in Italy in USD Million (2018–2030)

Figure 62: Market Size of Schizophrenia in Spain, USD Millions (2018–2030)

Figure 63: Market Size of Schizophrenia by Class in Spain in USD Million (2018–2030)

Figure 64: Market Size of Schizophrenia by Current and Emerging Therapies in Spain in USD Million (2018–2030)

Figure 65: Market Size of Schizophrenia in the UK, USD Millions (2018–2030)

Figure 66: Market Size of Schizophrenia by Class in the UK in USD Million (2018–2030)

Figure 67: Market Size of Schizophrenia by Current and Emerging Therapies in the UK in USD Million (2018–2030)

Figure 68: Market Size of Schizophrenia in Japan, USD Millions (2018–2030)

Figure 69: Market Size of Schizophrenia by Class in Japan, in USD Million (2018–2030)

Figure 70: Market Size of Schizophrenia by Molecules of Different Class in Japan in USD Million (2018–2030)

• Otsuka America Pharmaceutical/Lundbeck

• Intra-Cellular Therapies

• Sunovion Pharmaceuticals/Sumitomo Dainippon Pharma

• Merck/AbbVie/Schering-Plough Corporation/Allergan

• Otsuka Pharmaceutical

• Janssen Research & Development

• Gedeon Richter/AbbVie

• Alexza Pharmaceuticals

• Noven Pharmaceuticals/Hisamitsu Pharmaceutical

• Janssen Pharmaceuticals

• Alkermes

• Indivior

• Newron Pharmaceuticals

• Concert Pharmaceuticals

• Cerevel Therapeutics/Pfizer

• Roche

• Biogen

• Takeda

• SyneuRx International

• Janssen Pharmaceutical

• Lyndra Therapeutics

• Rovi Pharmaceuticals Laboratories

• Minerva Neurosciences

• Sunovion/PsychoGenics

• Acadia Pharmaceuticals

• Forum Pharmaceuticals

• BioXcel Therapeutics

• Avineuro Pharmaceuticals

• Alkermes

• Avanir Pharmaceuticals/Otsuka Pharmaceutical/Concert Pharmaceuticals

• H. Lundbeck A/S

• GW Research

• Boehringer Ingelheim

• Karuna Pharmaceuticals

• Celon Pharma

• Merck

• Corcept Therapeutics

• Boehringer Ingelheim

  • Tags:
  • Schizophrenia market
  • Schizophrenia market research
  • Schizophrenia market insight
  • Schizophrenia market trends
  • Schizophrenia market forecast
  • Schizophrenia market share
  • Schizophrenia pipeline drugs
  • Schizophrenia treatment algorithm
  • Schizophrenia drugs
  • Schizophrenia sales forecasting
  • Schizophrenia market size
  • Schizophrenia disease
  • Schizophrenia epidemiology
  • Schizophrenia

Forward to Friend

Need A Quote